

# AccuPlex™ SARS-CoV-2 Quality Solutions

ASSAY VERIFICATION AND ONGOING PERFORMANCE MONITORING FOR ROUTINE PATIENT TESTING

## HIGHLIGHTS

COMPATIBLE WITH CDC AND WHO CONSENSUS SEQUENCES FOR SARS-COV-2

REAL MAMMALIAN VIRUS ENABLES FULL-PROCESS QC FOR RT-PCR BASED VIRAL DISEASE ASSAYS.

NON-INFECTIOUS AND REPLICATION DEFICIENT; ENSURES SAFETY DURING ASSAY DEVELOPMENT AND END-USER QC APPLICATIONS

AccuPlex™ SARS-CoV-2 Verification Panel, coupled with the AccuPlex™ SARS-CoV-2 Reference Material, is a complete Quality Solution. Products contain positive materials directed against the published CDC and WHO consensus sequences (Table 1) and negative materials targeting the human RNase P gene.

**AccuPlex™ SARS-CoV-2 Verification Panel** is optimized for assay verification at installation by documenting test performance along the assay's range; enables laboratories to establish lower limits of detection, perform assay comparisons, and evaluate staff proficiency.

Product Description	Material Number	Pack Size	Concentration
AccuPlex™ SARS-CoV-2 Verification Panel	0505-0129	Positive 1 1 x 3 mL	100,000 copies/mL
		Positive 2 1 x 3 mL	10,000 copies/mL
		Positive 3 1 x 3 mL	1,000 copies/mL
		Negative 1 x 3 mL	Negative (RNase P gene)

**AccuPlex™ SARS-CoV-2 Reference Material**, is designed to measure day-to-day performance of the assay, providing both a positive and a negative reference solution.

Product Description	Material Number	Pack Size	Concentration
AccuPlex™ SARS-CoV-2 Reference Material Kit	0505-0126	Positive 5 x 1.5 mL	5,000 copies/mL
		Negative 5 x 1.5 mL	5,000 copies/mL (RNase P gene)


For custom requests, please contact [sarscov2@seracare.com](mailto:sarscov2@seracare.com).

### LGC SeraCare's SARS-CoV-2 AccuPlex solution:

- Non-infectious and replication deficient, enables safe handling in contrast to viral samples
- Fully-extractable with a real viral protein coat; superior to “naked” transcribed RNA
- Compatible with assays targeting CDC and WHO consensus sequences. (Table 1)
- Includes negative reference material for targeting sequences for the human RNase P gene
- 2 year stability at 2 - 8°C
- Customizable to sequences of interest to meet unique assay design requirements

**Table 1:** Regions included in AccuPlex Coronavirus (SARS-CoV-2) Positive Reference Material.

Region	Included Nucleotides
ORF1a	417..1899
	3094..3360
RdRp	13291..13560
	14700..15950
	18577..19051
E (Envelope)	25801..28200
N (Nucleocapsid)	27952..29873



Numbers refer to sequence of GenBank NC\_045512.2

To learn more about AccuPlex SARS-CoV-2 Quality Solutions visit: [www.seracare.com/SARSCoV2](http://www.seracare.com/SARSCoV2) or contact customer service at 800.676.1881

Not for In Vitro Diagnostic Use. Research Use Only.

## ABOUT SERACARE


TRUSTED SUPPLIER  
TO DIAGNOSTIC  
MANUFACTURERS AND  
CLINICAL LABS FOR  
OVER 30 YEARS.

HIGH-QUALITY  
CONTROL PRODUCTS,  
RAW BIOLOGICAL  
MATERIALS, AND  
IMMUNOASSAY  
REAGENTS.

INNOVATIVE TOOLS  
AND TECHNOLOGIES  
TO PROVIDE  
ASSURANCE IN  
DIAGNOSTIC ASSAY  
PERFORMANCE AND  
TEST RESULTS.

FOR MORE  
INFORMATION, PLEASE  
VISIT OUR WEBSITE:  
[WWW.SERACARE.COM](http://WWW.SERACARE.COM)

LGC SeraCare's AccuPlex recombinant material serves as a true full process molecular control for your diagnostic assays. Compatible with multiplexed RT-PCR and NGS-based assays, AccuPlex custom recombinant materials are constructed with a replication-deficient mammalian virus, producing a safe, non-infectious material (Figure 1). With a protein coat and lipid bilayer, these mammalian virus-based reference materials resemble the complexity of virus targets found in true patient samples.



**FIGURE 1:** 1) RNA sequence from the pathogenic virus of interest is chosen. 2) DNA synthesis and cloning occur to produce the recombinant RNA. 3) Recombinant RNA and helper RNA are co-transfected into the mammalian cells, allowing the encapsulation of recombined RNA. 4) Exocytosis of the mature enveloped non-infectious and replication deficient RNA virus containing the assay target RNA sequence of interest

## MOST 'PATIENT SAMPLE-LIKE' MATERIAL EVALUATES ENTIRE WORKFLOW

Unlike RNA-spiked buffer, or technologies that package viral RNA into a bacteriophage, the AccuPlex recombinant closely resembles the wild-type mammalian pathogenic virus. This enables the release of the viral genome at a similar rate to the wild-type virus during the nucleic acid sample preparation process. AccuPlex recombinant material mimics a real patient sample in your workflow, serving as a full-process control for your assay.

## ACCUPLEX SOLVES ASSAY DEVELOPMENT CHALLENGES

If you're developing diagnostics for emerging viral diseases and have the challenge of including safe, non-infectious controls in your test kit, partner with SeraCare's talented R&D team to produce your custom AccuPlex recombinant virus material (DNA or RNA-based). Utilizing your sequences of interest and product specifications, we will develop a custom solution which meets your unique requirements.

## ORDERING INFORMATION

To place an order, or learn more about our SARS-CoV-2 Quality Solutions, please contact us at +1.508.244.6400 and 800.676.1881 or email [customerservice@seracare.com](mailto:customerservice@seracare.com).